About this Research Topic
Non-infectious uveitis is a heterogeneous group of intraocular inflammatory diseases. The mainstay of treatment is corticosteroids, but in a large number of cases, due to resistance to this treatment and /or recurrence of inflammatory activity, long-term immunomodulatory drugs are required.
In the last 20 years the so-called biologic drugs, mainly the so-called anti-TNF alpha drugs, have been added to the group of conventional immunomodulatory drugs.
The introduction of these drugs into the therapeutic armamentarium was a revolution and made it possible to control inflammatory activity in cases that did not respond to classical therapeutic options. But there are still cases that do not respond to the current anti-TNF treatments and require the use of other biologics such as drugs that block interleukin-6, interleukin-1 or B-lymphocyte inhibitors.
There have been some recent advances in the treatment of uveitis. The so-called small molecules, such as kinase inhibitors, are promising drugs that are indicated for the treatment of some autoimmune systemic diseases. Some case reports have pointed out a potential benefit of these molecules in uveitis management. Moreover, we also have biological drugs which until now were administered intravenously and can now be administered subcutaneously. Finally, we are starting to use the so-called biosimilar drugs, i.e. molecules with a structure very similar to the reference biological drug and with a very probably equivalent efficacy.
In this Research topic we will make an update on the management of non-infectious uveitis, emphasizing and highlighting the most recent advances in the therapeutic armamentarium including small molecules, new routes of administrations and biosimilars, in order to explore their potential roles and indications.
We will be interested in any type of manuscript including case reports, original studies or reviews.
In the last 20 years the so-called biologic drugs, mainly the so-called anti-TNF alpha drugs, have been added to the group of conventional immunomodulatory drugs.
The introduction of these drugs into the therapeutic armamentarium was a revolution and made it possible to control inflammatory activity in cases that did not respond to classical therapeutic options. But there are still cases that do not respond to the current anti-TNF treatments and require the use of other biologics such as drugs that block interleukin-6, interleukin-1 or B-lymphocyte inhibitors.
There have been some recent advances in the treatment of uveitis. The so-called small molecules, such as kinase inhibitors, are promising drugs that are indicated for the treatment of some autoimmune systemic diseases. Some case reports have pointed out a potential benefit of these molecules in uveitis management. Moreover, we also have biological drugs which until now were administered intravenously and can now be administered subcutaneously. Finally, we are starting to use the so-called biosimilar drugs, i.e. molecules with a structure very similar to the reference biological drug and with a very probably equivalent efficacy.
In this Research topic we will make an update on the management of non-infectious uveitis, emphasizing and highlighting the most recent advances in the therapeutic armamentarium including small molecules, new routes of administrations and biosimilars, in order to explore their potential roles and indications.
We will be interested in any type of manuscript including case reports, original studies or reviews.
Keywords: non-infectious uveitis, TNF, inflammatory eye diseases
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
